- Home
- VTLE vs CMPX Comparison
VTLE vs CMPX Comparison
Compare VTLE & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTLE
- CMPX
- Stock Information
- Founded
- VTLE 2006
- CMPX 2014
- Country
- VTLE United States
- CMPX United States
- Employees
- VTLE N/A
- CMPX N/A
- Industry
- VTLE
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- VTLE
- CMPX Health Care
- Exchange
- VTLE Nasdaq
- CMPX Nasdaq
- Market Cap
- VTLE 631.5M
- CMPX 730.9M
- IPO Year
- VTLE 2011
- CMPX N/A
- Fundamental
- Price
- VTLE $15.05
- CMPX $3.82
- Analyst Decision
- VTLE Hold
- CMPX Strong Buy
- Analyst Count
- VTLE 11
- CMPX 7
- Target Price
- VTLE $26.11
- CMPX $14.43
- AVG Volume (30 Days)
- VTLE 546.0K
- CMPX 1.8M
- Earning Date
- VTLE 11-03-2025
- CMPX 11-05-2025
- Dividend Yield
- VTLE N/A
- CMPX N/A
- EPS Growth
- VTLE N/A
- CMPX N/A
- EPS
- VTLE N/A
- CMPX N/A
- Revenue
- VTLE $1,897,003,000.00
- CMPX N/A
- Revenue This Year
- VTLE $0.55
- CMPX N/A
- Revenue Next Year
- VTLE N/A
- CMPX N/A
- P/E Ratio
- VTLE N/A
- CMPX N/A
- Revenue Growth
- VTLE 1.85
- CMPX N/A
- 52 Week Low
- VTLE $12.30
- CMPX $1.27
- 52 Week High
- VTLE $36.72
- CMPX $4.86
- Technical
- Relative Strength Index (RSI)
- VTLE 43.58
- CMPX 48.41
- Support Level
- VTLE $14.97
- CMPX $3.63
- Resistance Level
- VTLE $16.28
- CMPX $3.95
- Average True Range (ATR)
- VTLE 0.66
- CMPX 0.27
- MACD
- VTLE -0.00
- CMPX -0.07
- Stochastic Oscillator
- VTLE 12.75
- CMPX 33.33
About VTLE Vital Energy Inc. par value $0.01 per share
Vital Energy is an independent energy company. Its business is focused on the acquisition, exploration, and development of oil and natural gas properties in the Permian Basin of West Texas. The Company has identified one operating segment: exploration and production.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.